What are the Implications of ERBB2 Status in Cancer Treatment?
Determining the ERBB2 status of a tumor is crucial for guiding treatment options. HER2-positive cancers can be treated with targeted therapies that specifically inhibit the HER2 protein. Trastuzumab (Herceptin) is a monoclonal antibody that targets HER2-positive cancer cells, marking them for destruction by the immune system. Other drugs, such as Pertuzumab and Lapatinib, have also been developed to target and inhibit the HER2 receptor, providing additional treatment options for patients with HER2-positive cancers.
